Skip to main content


We're creating a new version of this page. See preview

  • Oral Presentation
  • Open Access

Industrial scale production of chymosin with Aspergillus niger

  • 1
Microbial Cell Factories20065 (Suppl 1) :S31

  • Published:


  • Fermentation
  • Waste Water Treatment
  • Aspergillus Niger
  • Industrial Scale Production
  • Chymosin


Aspergillus niger has a long history as a producer of food-grade enzymes and is established as a GRAS (Generally Recognized As Safe) organism. As Chymosin has been created by nature to coagulate cow's milk, it is not surprising that chymosin is the most commonly used enzyme for cheesemaking. Since more than 10 years Chr. Hansen is producing chymosin by a large scale fermentation process.


The genome of A. niger was modified by inserting a prochymosin c-DNA via an expression vector. Chymosin is secreted as a fusion protein with glucoamylase and processed to the active protein during fermentation. After cultivation the biomass is inactivated by lowering the pH-value and separated by filtration. For concentration and purification of chymosin a one-step EBA (Expanded Bed Adsorption) chromatography is used. This new production process is illustrated in Figure 1.
Figure 1
Figure 1

Chymosin production process; fermentation and downstream processing.

During the last years the fermentation process was optimised by changing various parameters like feeding strategy and inoculation procedure of the Seed fermentor. The concentration step with an aqueous two-phase system with PEG (poly-ethylen-glycol) and the purification step with an ion-exchange chromatography step were replaced by one-step EBA chromatography.


The simplified downstream process reduced the costs for waste water treatment and increased the recovery yield. Due to its high quality, the unlimited availability and its competitiveness to other milk clotting enzymes the market share of fermentation produced chymosin (FPC) increased significantly over the last years.

Authors’ Affiliations

Department of Process Development, Ch. Hansen GmbH, Gr. Drakenburger Str. 93-97, Nienburg, D-31582, Germany


© Hellmuth; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.